The human spinal cord contains segregated sensory and motor pathways that have been difficult to quantify using conventional magnetic resonance imaging (MRI) techniques. Multiple sclerosis is characterized by both focal and spatially diffuse spinal cord lesions with heterogeneous pathologies that have limited attempts at linking MRI and behaviour. We used a novel magnetization-transfer-weighted imaging approach to quantify damage to spinal white matter columns and tested its association with sensorimotor impairment. We studied 42 participants with multiple sclerosis who each underwent MRI at 3 Tesla and quantitative tests of sensorimotor function. We measured cerebrospinal-fluid-normalized magnetization-transfer signals in the dorsal and lateral columns and grey matter of the cervical cord. We also measured brain lesion volume, cervical spinal cord lesion number and cross-sectional area, vibration sensation, strength, walking velocity and standing balance. We used linear regression to assess the relationship between sensorimotor impairment and MRI abnormalities. We found that the dorsal column cerebrospinal-fluid-normalized magnetization-transfer signal specifically correlated with vibration sensation (R = 0.58, P < 0.001) and the lateral column signal with strength (R = -0.45, P = 0.003). Spinal cord signal measures also correlated with walking and balance dysfunction. A stepwise multiple regression showed that the dorsal column signal and diagnosis subtype alone explained a significant portion of the variance in sensation (R(2) = 0.54, P < 0.001), whereas the lateral column signal and diagnosis subtype explained a significant portion of the variance in strength (R(2) = 0.30, P < 0.001). These results help to understand the anatomic basis of sensorimotor disability in multiple sclerosis and have implications for testing the effects of neuroprotective and reparative interventions.
The two major zona pellucida proteins of the zebrafish chorion, Zp2 and Zp3, are encoded by multicopy genes arranged in tandem arrays on chromosomes 20 and 2, respectively. Expression of these zp genes in zebrafish is oocyte specific, and we report herein that their activity in developing oocytes is dependent on conserved CCAAT box sites in their promoters. A 140-bp region immediately upstream of the transcription initiation site (position 1) of the zp2 genes has been homogenized by gene conversion and contains a single CCAAT box located at -138 that is necessary for promoter activity in oocytes residing in stage I and early stage II ovarian follicles as determined by microinjection of promoter constructs linked to a luciferase reporter gene. The zp3 gene promoters have two inverted CCAAT boxes located in a region of shared homology within the initial 175 nucleotides. Serial deletion of these sites resulted in incremental decreases in luciferase activity. Double-stranded oligonucleotides containing CCAAT box sequences from both genes formed CCAAT box-specific complexes with ovarian follicle extracts in an electrophoretic mobility shift assay. We also found that the expression of the separate zebrafish zp3b gene, more closely related to two oocyte-expressed medaka zpc genes than to the tandemly arrayed zebrafish zp3 genes, is not CCAAT box dependent. The significance that these results have in furthering our understanding of the regulation of zebrafish zp gene evolution and regulation is discussed.
Current treatment options for advanced cutaneous malignancies such as melanoma are low in efficacy. Immunotherapies have the potential to provide novel approaches to address this, particularly when used in combination. The authors have indicated no significant interest with commercial supporters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.